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Abstract Neutrophils are abundant, short-lived leuko-
cytes that play a key role in the immune defense against
microbial infections. These cells die by apoptosis following
activation and uptake of microbes and will also enter
apoptosis spontaneously at the end of their lifespan if they
do not encounter a pathogen. Adiponectin exerts anti-
inflammatory effects on neutrophil antimicrobial functions,
but whether this abundant adipokine influences neutrophil
apoptosis is unknown. Here we report that adiponectin in
the physiological range (1–10 lg/ml) reduced apoptosis in
resting neutrophils, decreasing caspase-3 cleavage and
maintaining Mcl-1 expression by stabilizing this anti-
apoptotic protein. We show that adiponectin induced
phosphorylation of AMP-activated kinase (AMPK), protein
kinase B (PKB), extracellular signal-regulated kinase
(ERK 1/2) and p38 mitogen activated protein kinase
(MAPK). Pharmacological inhibition of AMPK, PKB and
ERK 1/2 ablated the pro-survival effects of adiponectin and
treatment of neutrophils with an AMPK specific activator
(AICAR) and AMPK inhibitor (compound C) respectively
decreased and increased apoptosis. Finally, activation of
AMPK by AICAR or adiponectin also decreased ceramide
accumulation in the neutrophil cell membrane, a process
involved in the early stages of spontaneous apoptosis,
giving another possible mechanism downstream of AMPK
activation for the inhibition of neutrophil apoptosis.
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Introduction
Neutrophils, the most numerous immune cells in the cir-
culation, represent the first line of protection against
microbial and fungal infection. These post mitotic cells are
characterised by a very short lifespan, undergoing consti-
tutive apoptosis within 5 days after leaving the bone mar-
row [1]. However their apoptosis can be delayed at sites of
infection by a range of factors including bacterial products
such as lipopolysaccharide (LPS) [2], pro-inflammatory
cytokines [3, 4] and hypoxia [5], ostensibly to extend their
functional lifespan. However, the tight regulation of
apoptosis and the prompt removal of apoptotic neutrophils
are also central to the resolution of the inflammatory
response and prevention of tissue damage and chronic
inflammation [6, 7].
Neutrophils express very few Bcl-2 family members,
with Mcl-1 appearing to be the most relevant in regulating
their survival [8]. The level of this protein positively cor-
relates with neutrophil lifespan [9] and its loss accelerates
neutrophil apoptosis [10, 11]. Due to its characteristic
PEST domain, this protein is subject to rapid turnover by
the proteasome [12], however the activation of several
signalling pathways can modulate Mcl-1 levels therefore
influencing neutrophil longevity. In particular, the activa-
tion of the MAPK ERK 1/2 and the PI3K/PKB axis fol-
lowing treatment of cells with LPS [13], TLR agonists [14]
and granulocyte macrophage colony-stimulating factor
(GM-CSF) [15], results in the maintenance of Mcl-1. Both
ERK 1/2 and PI3K/PKB have been found to increase Mcl-1
protein levels mainly by stabilizing the protein through
specific phosphorylations which delay Mcl-1 degradation
and increase its half-life [16].
p38 MAPK is also phosphorylated in response to LPS
[13] and hypoxia [5, 17], though its anti-apoptotic effect is
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less clear as its pharmacological inhibition further increa-
ses LPS anti-apoptotic effects [13]. More recently we have
shown that inhibition of cyclin dependent kinase (CDK) 9
results in loss of Mcl-1 [18], identifying the cell cycle
independent CDKs as novel regulators of neutrophil
apoptosis. Additional proteins such as survivin [19] and
proliferating cell nuclear antigen [20] have been proposed
as regulators of neutrophil lifespan, as they are present in
mature neutrophils and their expression correlates with
decreased apoptosis.
Adiponectin is an abundant adipokine which belongs to
the C1q/tumor necrosis factor superfamily [21, 22]. The
full-length isoform displays anti-inflammatory properties
on neutrophils as it inhibits superoxide generation [23] and
production of the chemokine CXCL8 [24]. The main sig-
naling pathway activated by adiponectin and responsible
for its actions in several cell types is proposed to be AMPK
[25]. To date there are no reports of a role of adiponectin or
AMPK in regulating neutrophil apoptosis. In this study we
show that adiponectin delayed apoptosis of human neu-
trophils by activating AMPK, PKB, ERK 1/2, revealing for
the first time that signalling through AMPK enhances




Human recombinant adiponectin, was purchased from
Enzo Life Sciences (Farmingdale, NY), with contamina-
tion from LPS certified to be less than 0.1 EU/lg purified
protein. To ensure no artefactual effects from LPS con-
tamination, Polymyxin B (10 lg/ml) (Millipore, Billerica,
MA) was added to the cells 30 min before treatment with
adiponectin. Percoll, RPMI 1640 medium, L-glutamine,
penicillin–streptomycin, propidium iodide solution (PI),
dimethylsulfoxide (DMSO), fetal calf serum (FCS), goat
serum, cycloheximide, protease inhibitor cocktail (cata-
logue number P8348) and phosphatase inhibitor cocktails
(catalogue numbers P0044 and P5726), the AMPK inhib-
itor compound C (6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-
pyridin-4-ylpyrazolo[1,5-a]pyrimidine) and the p38 inhib-
itor SB202190 and all buffers and salt solutions were
purchased from Sigma-Aldrich (Poole, UK). The MEK1
inhibitor PD98059 was from Cell Signaling Technology
(Beverly, MA), the PI3K inhibitor LY294002 was from
Millipore, Annexin V-FITC was obtained from BD Bio-
sciences (San Jose, CA), the AMPK activator AICAR
(5-Aminoimidazole-4-carboxamide 1-b-D-ribofuranoside)
and the anti-ceramide antibody (clone MID15B4) were
from Enzo Life Sciences. FITC-conjugated anti-active
caspase-3 antibody was purchased from BD Biosciences
(San Jose, CA). Antibodies against phosphorylated AMPK
(Thr172), total AMPK, phosphorylated PKB (Ser473), total
PKB, phosphorylated ERK1/2 (Thr202/Tyr204), total ERK
and phosphorylated p38 MAPK (Thr180/Tyr182), were all
purchased from Cell Signaling Technology. The antibodies
against total p38 MAPK and Mcl-1 (clone S-19) were from
Santa Cruz Biotechnology (Santa Cruz, CA) and the anti-
body against actin was obtained from Sigma-Aldrich. The
secondary antibody FITC-labelled goat anti-mouse was
obtained from Southern Biotech (Birmingham, AL) and the
isotype control mouse IgM was from Dako (Ely, UK).
Neutrophil isolation and treatment
Heparinised peripheral blood was obtained from healthy
human donors and all volunteers gave written informed
consent prior to their participation. The study was approved
by the local research ethics committee. Neutrophils were
isolated by density centrifugation as previously described
[26]. The purity of isolated neutrophils was determined by
differential staining using a commercial May-Grunwald
Giemsa stain (Diff-Quick, Baxter Healthcare, UK) and
light microscopy and was routinely greater than 97 %. For
all studies neutrophils were resuspended in RPMI-1640
medium containing 2 Mm L-glutamine, 100 U/ml penicil-
lin, 100 lg/ml streptomycin supplemented with 10 % heat-
inactivated FCS.
Isolated neutrophils were adjusted to a concentration of
2 9 106/ml and were dispensed into a 96-well round bot-
tomed plate (Sarstedt, Leicester, UK) and incubated with
either adiponectin at the indicated doses or vehicle (sterile
distilled water) for the indicated incubation times. The
kinase inhibitors compound C, PD98059 and SB202190
were added to the culture 30 min before the addition of
adiponectin at a concentration of 10 lM. Cycloheximide
was added 30 min before the addition of adiponectin at the
final concentration of 5 lg/ml. Compound C (10 lM) and
AICAR (1 mM) were also added to purified neutrophils for
20 h to determine whether specific AMPK activation/
inhibition affected neutrophil apoptosis.
Assessment of neutrophil apoptosis
Apoptosis was determined by three methods. For Annexin
V binding, which identifies cells with phosphatidylserine
exposed on the cell surface, cells were washed with PBS
and centrifuged at 2509g for 5 min at 4 C, then resus-
pended in 100 ll of Annexin V buffer (10 mM HEPES, pH
7.4; 140 mM NaCl; 2.5 mM CaCl2). 1 ll of AnnexinV-
FITC was added per well (1 9 105 cells) and cells were
incubated in the dark at room temperature for 10 min, after
which PI was added at a final concentration of 5 lg/ml.
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Fluorescence was analyzed by flow cytometry (BD Accuri
C6 Flow Cytometer, Accuri Cytometers Inc., Ann Arbor,
MI), with cells that were Annexin V positive but PI neg-
ative taken as apoptotic.
Apoptosis was also measured by assessment of cells
with the nuclear morphology characteristic of apoptotic
neutrophils, i.e. collapse of the multi-lobed nucleus to a
single densely stained body. Cytospin preparations were
differentially stained using a commercial May-Grunwald
Giemsa stain and assessed for apoptotic morphology by
light microscopy using an Olympus IX71 microscope.
Images were taken at 409 magnification.
Apoptotic neutrophils express active caspase 3. To detect
active caspase 3 cells were fixed and permeabilised using the
Fix and Perm kit from Life technologies (Carlsbad, CA),
according to the manufacturer’s instructions. Cells were
washed and resuspended in 100 ll of PBS, then FITC-con-
jugated anti-active caspase-3 or isotype matched antibody
were added to a final concentration of 2.5 lg/ml and incubated
for 30 min at room temperature. Neutrophils were washed and
immunofluorescence analyzed by flow cytometry.
Protein extraction and western blotting
Neutrophils were spun at 4,000 rpm for 4 min (MSE mi-
crocentaur) prior to resuspension in lysis buffer (20 mM
MOPS, 50 mM NaF, 50 mM b-glycerophosphate, 50 mM
Na3VO4, 1 % Triton X-100, 1 mM DTT, 1 mM AEBSF
and 1 % protease [27] and phosphatase inhibitor cocktails
[28]). Lysis of neutrophils was performed on ice for 30 min
with occasional vortexing. The lysates were centrifuged at
13,000 rpm for 1 min (MSE microcentaur) and the super-
natant collected and combined with an equal volume of
SDS-PAGE sample buffer (125 mM HCl pH 6.8, 5 %
glycerol, 2 % SDS, 1 % b-mercaptoethanol, 0.003 % bro-
mophenol blue) and boiled for 10 min. Proteins were
separated by SDS-PAGE and transferred onto PVDF
membranes. Non-specific protein binding was blocked
using either 5 % BSA for the phosphospecific antibodies or
5 % non-fat milk for the remaining antibodies. Membranes
were incubated with primary antibodies to phosphorylated
AMPK (1:1,000), total AMPK (1:1,000), phosphorylated
PKB (1:1,000), total PKB (1:1,000), phosphorylated ERK
1/2 (1:1,000), total ERK (1:1,000), phosphorylated p38
MAPK (1:1,000), total p38 MAPK (1:500), Mcl-1
(1:1,000), or b-actin (1:5,000) overnight at 4 C. After
washing, membranes were incubated with appropriate
secondary antibodies (ECLTM anti-rabbit or anti-mouse
IgG; GE Healthcare, Uppsala, Sweden) for 1 h at room
temperature. Proteins were visualized by ECL according to
manufacturer’s instructions (GeneFlow, Lichfield, UK).
When necessary, membranes were subjected to mild
stripping (stripping buffer: 200 mM glycine, 0,1 % SDS,
1 % Tween 20). Densitometric analyses were performed
using Image J software.
Surface detection of ceramide
Surface accumulation of ceramide was analyzed by indirect
immunofluorescence staining after 20 h of treatment.
Briefly, neutrophils were washed with PBS and monoclonal
antibody against ceramide was added at a final concentra-
tion of 10 lg/ml and cells were incubated for 30 min at
4 C. After the incubation cells were washed with PBS and
spun at 2509g for 5 min at 4 C, then resuspended in PBS.
Nonspecific binding sites were blocked by addition of 3 ll
of goat serum for 5 min before addition of the secondary
FITC-conjugated goat anti-mouse antibody (10 lg/ml) for
a further 30 min. Samples were washed with PBS and
analyzed by flow cytometry.
Statistical analyses
Data were analyzed using GraphPad Prism 4 software
(GraphPad Software Ltd, La Jolla, CA). Two-tailed paired
Student’s t test was used to compare two groups of paired
samples, whereas repeated measures ANOVA was used to
analyze more than two groups of matched samples, followed
by Tukey’s multiple comparison test. Results are expressed
as mean values ± standard error of the mean (SEM). A
p value of less than 0.05 was accepted as significant.
Results
Adiponectin inhibits neutrophil apoptosis
We found that addition of adiponectin in the physiological
range (1–10 lg/ml [29, 30]) reduced neutrophil apoptosis in a
dose dependent manner after both 6 and 20 h incubation
(Fig. 1a, b). At a higher concentration (20 lg/ml) adiponectin
did not further increase the rescue from apoptosis (data not
shown). Therefore, 10 lg/ml adiponectin was used in the
remaining experiments. Examination of the nuclear mor-
phology of neutrophils confirmed the anti-apoptotic effect of
adiponectin. After 20 h of incubation, control neutrophils
displayed fragmented or mono-lobed nuclei (indicated with
arrows) whereas a greater number of adiponectin-treated
neutrophils retained the multi-lobed nuclear morphology of
healthy, non-apoptotic cells (Fig. 1c, d). Caspase-3 represents
a central element in neutrophil constitutive apoptosis as its
activation induces the characteristic changes in the apoptotic
cell, including the final DNA fragmentation [31]. To assess
whether adiponectin inhibited neutrophil apoptosis through
decreased activation of caspase-3, we stained neutrophils with
an antibody against its cleaved active form. As shown in
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Fig. 1e, after 20 h adiponectin significantly decreased the
percentage of cells displaying active caspase-3.
Adiponectin treatment prevents loss of Mcl-1
expression
Mcl-1 is the Bcl-2 family protein most involved in
regulating neutrophil apoptosis [9] and its expression is
increased by several anti-apoptotic stimuli [16]. Thus, we
evaluated whether adiponectin-mediated inhibition of
neutrophil apoptosis was associated with upregulation of
Mcl-1. As shown in Fig. 2a, b, adiponectin-treated neu-
trophils exhibited higher expression of Mcl-1 than
untreated cells after both 6 and 20 h of incubation. To
determine whether this was achieved through improved
stability of Mcl-1, we pre-treated the cells with the
Fig. 1 Adiponectin delays neutrophil spontaneous apoptosis. Human
neutrophils were treated with adiponectin at the concentratiosn shown
and assessed for the presence of apoptotic cells by staining for
Annexin V binding at a 6 h and b 20 h incubation (n C 6
experiments); c Apoptosis was also assessed after 20 h by examina-
tion of differentially stained cells for nuclear morphology
characeristic of apoptotic neutrophils (n = 5 experiments) and
d representative images are shown: arrows indicate late apoptotic
neutrophils; e The presence of active caspase 3 was also assessed by
immunostaining. In a, b, c and e data are mean ± SEM and
*p \ 0.05 and **p \ 0.01
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protein synthesis inhibitor cycloheximide (5 lg/ml) and
assessed Mcl-1 levels after 6 h of incubation. As previ-
ously reported [16], we found that cycloheximide treat-
ment alone reduced Mcl-1 protein levels and we
observed that addition of adiponectin to cycloheximide-
treated cells resulted in an increase in Mcl-1 levels,
confirming that adiponectin decreased the turnover of
Mcl-1 (Fig. 2c).
Adiponectin activates AMPK, PKB and the MAPKs
ERK 1/2 and p38
The main intracellular signalling pathways previously
reported to be activated by adiponectin are AMPK and p38
MAPK [23, 32]. We investigated whether adiponectin
could promote the phosphorylation of these two kinases,
plus other kinases known to modulate neutrophil apoptosis,
Fig. 2 Adiponectin maintains Mcl-1 protein levels by increasing
Mcl-1 protein stability. Representative western blots and densitomet-
ric analyses showing the changes in the level of Mcl-1 in freshly
isolated, untreated and adiponectin-treated neutrophils after 6 h
(a) and 20 h (b) of incubation. c Representative western blots and
densitometric analysis showing the effect of cycloheximide (5 lg/ml)
on the adiponectin-mediated increase in Mcl-1. Densitometric
analyses are expressed as the ratio of Mcl-1 to b-actin. Data are
mean ± SEM and *p \ 0.05, **p \ 0.01, ***p \ 0.001
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namely the PI3K substrate PKB and ERK 1/2 MAPK [13,
14, 33]. Studies of the time course of kinase activation
showed that adiponectin transiently activated AMPK for up
to 15 min (Fig. 3). Adiponectin also induced the phos-
phorylation of PKB, ERK 1/2 and p38 MAPKs, though the
kinetics of activation were different and were maximal at
30 min of adiponectin treatment (Fig. 3).
AMPK, PKB and ERK 1/2 inhibition block the anti-
apoptotic effect of adiponectin
To assess whether the activation of AMPK, PKB, ERK 1/2
and p38 MAPK were all required for adiponectin’s anti-
apoptotic effects, we used selective pharmacological inhib-
itors against these kinases prior to the addition of adiponectin
and monitored neutrophil apoptosis by Annexin V/PI
staining after 20 h. The data show that the adiponectin-
mediated increase in neutrophil survival was blocked by
inhibition of AMPK, PI3K/PKB and ERK 1/2, but not p38
MAPK (Fig. 4).
As the phosphorylation of AMPK induced by adipo-
nectin preceded the phosphorylation of PKB, ERK 1/2 and
p38 (Fig. 3), it was important to investigate the role of
AMPK in adiponectin-mediated activation of these sig-
nalling pathways. We therefore pre-incubated neutrophils
with the AMPK inhibitor compound C for 30 min prior to
addition of adiponectin for a further 30 min and assessment
of the phosphorylation of PKB, ERK 1/2 and p38 MAPK.
Compound C on its own led to an increase in the phos-
phorylation of PKB, ERK 1/2 and p38 compared to the
control although this only reached statistical significance
for phosphorylation of p38. Importantly, AMPK inhibition
Fig. 3 Adiponectin induces
phosphorylation of AMPK,
PKB, ERK 1/2 and p38 MAPK.
Representative western blots
and densitometric analyses
showing time courses for
AMPK, PKB, ERK 1/2 and p38
phosphorylation induced by
adiponectin. Densitometric
analyses are expressed as the
ratio of phosphorylated to
unphosphorylated forms of the
proteins (n = 4). Data are
mean ± SEM and *p \ 0.05,
**p \ 0.01, ***p \ 0.001
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by compound C led to complete inhibition of adiponectin
induced phosphorylation of PKB, with no significant effect
on ERK or p38, suggesting that AMPK activation could be
upstream of PKB activation (Fig. 5a). We then stimulated
neutrophils with the pharmacological activator of AMPK,
AICAR (1 mM) for 30 min, but AICAR had no effect on
the phosphorylation of PKB (Fig 5b) or ERK 1/2 and p38
phosphorylation (data not shown). From these data we
cannot conclusively conclude that AMPK activation by
adiponectin lies upstream of PKB activation.
AMPK activation is a survival signal for neutrophils
AMPK activation is triggered by low intracellular ATP
levels [34] and it usually induces apoptosis in cancer cells
[35] but enhances survival in other post mitotic cells, such
as neurons [36]. To further investigate the role of AMPK
itself in neutrophil apoptosis, we evaluated the percentage
of apoptotic cells in the presence of the pharmacological
AMPK activator AICAR and its inhibitor compound C.
AMPK activation decreased neutrophil apoptosis as asses-
sed by caspase-3 activation after 20 h incubation (Fig. 6a),
but did not affect Mcl-1 levels (data not shown). Although
treatment with compound C alone gave a slight but non-
significant increase in apoptosis as measured by Annexin V
staining (Fig. 4), when apoptosis was measured by caspase
3 activation the increase reached significance (Fig. 6a).
Mcl-1 levels were decreased by addition of compound C in
adiponectin-treated cells, but were not significantly affected
by compound C on its own (Fig. 6b, c).
Adiponectin, AICAR and compound C alter ceramide
accumulation in the membrane
Ceramide is a sphingolipid which physiologically accu-
mulates in neutrophils inducing their apoptosis [37, 38], in
particular its assembly in membrane lipid rafts accelerates
death receptor-induced cell death [38, 39]. Ceramide gen-
eration has already been demonstrated to be regulated by
AICAR [40], compound C [41] and adiponectin itself [42],
hence we analysed the content of ceramide present on the
surface of neutrophils after 20 h of incubation with these
compounds. We also assessed ceramide accumulation in
the presence of inhibitors of PI3K, ERK 1/2 and p38
MAPKs to determine whether the signaling pathways
activated by adiponectin could contribute to altered cera-
mide accumulation (Fig. 7). AICAR and compound C
respectively decreased and increased ceramide levels on
Fig. 4 Anti-apoptotic effects of
adiponectin are mediated by
AMPK, PKB and ERK 1/2
activation. Neutrophils were
incubated with pharmacological
inhibitors of AMPK (compound
C, 10 lM), PI3K/PKB
(LY294002, 10 lM), ERK
MAPK (PD98059, 10 lM), or
p38 MAPK (SB202190, 10 lM)
prior to treatment with
adiponectin (10 lg/ml).
Apoptosis was measured by
Annexin-V/PI staining after
20 h of incubation (n = 7).
Data are mean ± SEM and
*p \ 0.05, **p \ 0.01,
***p \ 0.001
Apoptosis (2013) 18:1469–1480 1475
123
neutrophil membranes, indicating the possible mechanism
by which AMPK activation could influence neutrophil
apoptosis. Adiponectin also significantly diminished cer-
amide accumulation, although its effect was less marked
than AICAR treatment (Fig. 7). In contrast, PI3K, ERK
1/2 and p38 inhibition did not affect ceramide content
(Fig. 7).
Discussion
Neutrophil constitutive apoptosis can be modulated by a
range of factors which interfere with pro- and anti-apop-
totic signalling pathways, resulting in extended or short-
ened lifespan [43]. Our findings reveal that adiponectin is
another systemic factor that negatively influences neutro-
phil apoptosis in vitro. Moreover our data suggest that this
is mediated by mechanisms that include stabilisation of
Mcl-1 and reduced accumulation of cermide in the cell
membrane, the latter mediated by AMPK activation.
Adiponectin has been extensively studied with regard to
its anti-inflammatory actions [29], although some groups
have also described pro-inflammatory effects, for example
on dendritic cells [44], macrophages and lymphocytes [32].
Contradictory results exist in relation to its effect on
apoptosis: adiponectin induces apoptosis in several tumor
cell lines [45–47] as well as activated T lymphocytes [48],
whereas it protects post-mitotic cell types from death, such
as neurons [49], and endothelial cells [50] when challenged
with pro-apoptotic agents. Moreover, an association
between low serum adiponectin concentration and high
levels of apoptotic markers in the blood was reported
recently [24]. Taking into account this literature, the anti-
apoptotic effect indicated here for adiponectin on neutro-
phils, a post-mitotic cell, is consistent with the previous
findings for its effects on non-proliferating cells.
Fig. 5 Adiponectin may not activate PKB, ERK 1/2 and p38 via
AMPK. Representative western blots and densitometric analyses
showing a phosphorylation of PKB, p 42/44 ERK and p38 in response
to treatment of neutrophils with adiponectin (10 lg/ml) in the absence
or presence of compound C (10 lM) (n = 6) and b effect of AICAR
treatment (1 mM) on PKB phosphorylation (n C 3). Densitometric
analyses are expressed as the ratio of the phosphorylated to
unphosphorylated forms of the proteins. Data are mean ± SEM and
*p \ 0.05, **p \ 0.01, ***p \ 0.001
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Whether inhibition of neutrophil apoptosis would be
pro- or anti-inflammatory in vivo remains to be established.
At times of infection extending neutrophil lifespan could
be beneficial as it would aid removal of the infective agent,
but as others have reported inhibition of neutrophil func-
tions such as superoxide generation [23] by adiponectin,
keeping these cells alive but non-functional could be pro-
inflammatory. This conclusion is supported clinically as
adiponectin levels are higher in certain chronic inflamma-
tory diseases, such as chronic obstructive pulmonary dis-
ease (COPD) [51], in which reduced levels of neutrophil
apoptosis are well documented [52, 53].
This study shows that adiponectin enhances neutrophil
survival by decreasing the cleavage of caspase-3 and
reducing Mcl-1 degradation and accumulation of ceramide
in the cell membrane. The main anti-apoptotic signalling
pathways activated by adiponectin were shown to be
AMPK, PI3K/PKB and the MAPK ERK 1/2. The latter two
pathways are already known to increase Mcl-1 half-life and
thereby reduce neutrophil apoptosis [16]. Phosphorylation
of p38 was also induced by adiponectin and this pathway
has been shown to enhance NF-kB activity, which is
known to inhibit neutrophil apoptosis [54, 55], either by
phosphorylation of RelA/p65 [56] or by promoting IKKb
degradation [57]. Adiponectin itself has been reported to
activate NF-kB under certain conditions [58, 59]. However
here we show that p38 inhibition did not block the anti-
apoptotic effects of adiponectin.
Our data also suggest that AMPK activation was not
responsible directly for the adiponectin-mediated phos-
phorylation of PKB, ERK 1/2 and p38 as the pharmaco-
logical AMPK activator AICAR did not induce activation




with the AMPK activator
AICAR (1 mM) or inhibitor
compound C (10 lM).
a Apoptosis was measured by




showing the effect of compound
C and adiponectin on Mcl-1
levels after 6 h treatment.
Densitometric analyses are
expressed as the ratio of Mcl-1
to b-actin (n = 6). Data are
mean ± SEM and *p \ 0.05,
**p \ 0.01
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of these pathways. Although the addition of the AMPK
inhibitor compound C inhibited adiponectin-mediated
phosphorylation PKB, it also led to an increase in p38
phosphorylation and a slight but non significant effect on
ERK and PKB when added to cells in the absence of
adiponectin. These indicate that compound C may have off
target effects that led to activation of these kinases and
compound C has been reported to exert effects independent
of AMPK activation by others [60–62]. Therefore we
cannot conclude with certainty that activation of PKB,
ERK1/2 and p38 occur downstream of AMPK activation
and the AICAR data certainly do not support this.
To further investigate the role of AMPK activity in
regulating neutrophil apoptosis we demonstrated that the
activating agent AICAR reduced neutrophil apoptosis
without increasing Mcl-1 stabilization. However, the lit-
erature contains reports that both AICAR and compound C
have effects upon the generation of ceramide within the
cell membrane, through modulation of sphingomyelinase
[40, 41]. We confirmed these results in neutrophils and also
showed that adiponectin significantly decreased the accu-
mulation of ceramide in neutrophil cell membranes. These
findings are potentially important as we have previously
shown a key role for ceramide generation in triggering lipid
raft coalescence and activation of death receptor signalling
in neutrophils during constitutive apoptosis [37]. Impor-
tantly, inhibition of PI3K, ERK 1/2 and p38 did not
influence ceramide accumulation, suggesting that AMPK is
the only modulator of ceramide level among the pathways
activated by adiponectin.
In conclusion, our work demonstrates that adiponectin
exerts an anti-apoptotic effect on neutrophils mainly by
activating AMPK, PI3K/PKB and ERK pathways and
preliminary data suggest that both stabilisation of Mcl-1
and reduced ceramide accumulation in the cell membrane
are involved.
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